Compare Enveric Biosciences Inc (ENVB) vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) (UGP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) trades at $7.78 (market cap $8.28B). The key difference: Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) is far larger — about 1237.7× Enveric Biosciences Inc's market cap, and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) pays a 4.85% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share) for 0 Days on average.
| ENVB | UGP | |
|---|---|---|
Market Cap | $6.69M | $8.28B |
Volume | 41,141 | 3,583,950 |
Sector | Health | Energy |
52-Week High | $10.80 | $7.79 |
52-Week Low | $1.27 | $3.63 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | -$1.60M | $10.35B |
Dividend Yield | — | 4.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Ultrapar Participacoes S.A. (New) American Depositary Shares (Each representing one Common Share)
Ultrapar is a Brazilian company with fuel distribution, liquefied petroleum gas, and chemical businesses. Its consumer-facing operations include fuel and gas distribution brands.
Read more on UGP →
